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Objective: The study was conducted to assess the efficacy and rate of complications of endovenous laser treatment (EVLT)
of the short saphenous vein (SSV).
Methods: During a 17-month period, 210 (187 patients) with SSV incompetence documented by duplex ultrasound
studies were treated with EVLT using a 980-nm diode laser. Duplex ultrasound examinations were performed on the day
of the procedure, within the first week, and 2 to 11 months after the procedure (mean follow-up, 4 months). Clinical
examinations were performed at 2 weeks and 6 weeks. Patients were assessed for deep venous thrombosis (DVT), nerve
injury, and resolution of symptoms.
Results:All procedures were technically successful, and in the 126 patients (60%) who completed final follow-up scanning,
96% of SSVs remained closed. Three patients (1.6%) had numbness at the lateral malleolus at the 6-week follow-up. DVT,
defined as a tail of thrombus protruding into the popliteal vein, was not detected in any limbs at the initial duplex study,
but was noted in 12 limbs (5.7%) at the 1-week follow-up examination. Nine patients were treated with 3 days to 3
months of fractionated heparin and Coumadin (Bristol-Myers Squibb, Princeton, NJ), and there were no DVT
extensions or pulmonary emboli. The anatomic configuration of the saphenopopliteal junction was the only factor
predictive of DVT.
Conclusions: Intermediate-term results of EVLT of the SSV demonstrate that the technique is effective at eliminating SSV
reflux and affording symptomatic relief. The incidence of nerve injury is low, but the incidence of DVT is higher than
reported for the great saphenous vein. Anatomic features of the SSV may predict patient risk for DVT. (J Vasc Surg
2007;45:795-803.)Venous incompetence is a common medical condition
that causes lower extremity pain, fatigue, and swelling in
millions of patients. Valvular incompetence of the great
saphenous vein (GSV) is the most frequent cause of venous
insufficiency, but incompetence of the short saphenous
vein (SSV) is not uncommon: up to 20% of patients with
varicose veins have incompetence of the SSV.1
Endovenous laser therapy (EVLT) of the GSV has been
proven to be safe, with long-term results that are compara-
ble or superior to traditional high ligation and stripping.2-4
Several large series have included SSV ablations, but studies
looking specifically at the success rate and risks associated
with laser ablation of the SSV have included only small
numbers of patients.5
Anatomic differences between the saphenofemoral
junction and the saphenopopliteal junction, as well as the
proximity of the sural nerve to the SSV, are two reasons why
study results of endovenous laser ablation of the GSV may
not be applicable to the SSV. The purpose of this study is to
report on the effectiveness and safety of laser ablation of the
SSV from a large number of patients from a single center.
From Lake Washington Vascular Surgeonsa, and Mountain-Whisper-Light
Statistical Consultingb.
Competition of interest: none.
Presented at the Twenty-first Annual Meeting of The Western Vascular
Society, La Jolla, Calif, Sep 16-19, 2006.
Reprint requests: Kathleen D. Gibson, MD, Lake Washington Vascular
Surgeons, 1135 116th Ave NE, Suite 305, Bellevue, WA 98004(e-mail:
drgibson@lkwv.com).
0741-5214/$32.00
Copyright © 2007 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2006.11.059METHODS AND MATERIALS
Patient selection and criteria. The study was a pro-
spective consecutive enrollment of 187 patients (210)
limbs that underwent laser ablation of the SSV. Patients had
preoperative documentation of SSV reflux using a GE
LOGIQ 9 duplex ultrasound (GE Healthcare, Waukesha,
Wisc). It was noted during the study period that our
patients had three anatomic patterns of the SSV, which we
have classified as type A, B, and C (Fig 1). Anatomic
classification was made before ablation:
● Type A: a saphenopopliteal junction with no signifi-
cant branches;
● Type B: a saphenopopliteal junction with a large ex-
tension Giacomini vein;
● Type C: no direct termination into a deep vein (saphe-
nopopliteal or saphenofemoral junction), and the SSV
continued as a Giacomini vein above the popliteal
fossa.
These SSV anatomic classifications are not standard or
previously defined and are classifications that we have pro-
posed.
All patients had a clinical evaluation to document vari-
cosities and symptoms according to the CEAP classifica-
tion. Digital photographs were obtained to document var-
icosities, skin changes, and ulceration. Patients with
significant peripheral arterial disease, significant deep ve-
nous insufficiency with obstruction, and pregnant patients
were not treated.
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with oral or intravenous benzodiazepine sedation, or both.
Patients were placed in the prone position, and the SSV was
Fig 1. Anatomic patterns of the short saphenous vein(SSV).accessed using a micropuncture technique under ultra-sound guidance. A 4F sheath was introduced into the SSV
and advanced to cover the entire desired treatment length.
A laser fiber was then exposed out of the tip of the sheath,
and the sheath and fiber were pulled back to ’2 cm from the
saphenopopliteal junction.
Ultrasound guidance was used to deliver perivenous
tumescence along the entire length of the vein. Collapse of
the saphenopopliteal junction was verified and that the cuff
of tumescent fluid was at least 2 cm in diameter around the
SSV. After adequate tumescent cuff was achieved around
the vein, laser energy was delivered with a 980-nm diode
laser (AngioDynamics Inc, Queensbury, NY) in continuous
mode. Pullback was at a rate of 3-mm to 5-mm per second,
with active power of 10 to 14 watts.
At least one concomitant treatment, such as EVLT of
the GSV, perforator ligation, microphlebectomy, or sclero-
therapy, or a combination, was performed on 94% of pa-
tients (Table I) at the same time as EVLT of the SSV. No
patients had simultaneous treatment of the contralateral
limb.
After completion of the procedure, compression pads
were placed over the treated area, and a 20 to 30 mm Hg
graduated compression stocking was placed on the treated
limb. Patients ambulated immediately and were encour-
aged to walk on the day of the procedure. Patients wore the
class II compression stockings 24 hours a day for 2 days and
then during the daytime for 2 weeks. Nonsteroidal anti-
inflammatory drugs were encouraged for the first 2 weeks
after therapy.
Follow-up protocol. Patients had a duplex ultra-
sound examination using a GE LOGIQ 9 machine on the
day of the procedure and again 2 to 4 days later. The
original design of the study was to obtain a final duplex
ultrasound study 3 months after the procedure; however,
the final follow-up scan was at 2 to 11 months postproce-
dure (mean follow-up, 4.0 months). The duplex scans
assessed for the presence a DVT and for SSV closure. A
DVT was defined as clot extending beyond or into the
saphenopopliteal junction. If a DVT was detected at any
time during follow-up, additional follow-up scans were
obtained to rule out progression of the thrombus.
Patients had clinical follow-up visits at 2 weeks and 6
weeks after the procedure. At this visit, the extremity was
examined and photographed, and the presence or absence
of varicosities, skin changes, and ulceration was noted.
Patients were examined for nerve injuries and were asked
about changes in their level of extremity discomfort com-
Table I. Concomitant treatments
Treatment Limbs, n (%)
GSV EVLT 156 (74)
Sclerotherapy 120 (57.1)
Perforator Ligation 136 (64.8)
Microphlebectomy 35 (16.7)
GSV, Great saphenous vein; EVLT, endovenous laser treatment.pared with before the procedure.
laser
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ized estimating equations (GEE) was used to quantify the
association of selected risk factors with the incidence of
DVT and closure. The risk factors considered included
gender, leg side (right, left), preoperative presence of ulcer,
preoperative presence of stasis, preoperative presence of
pain, anatomy type (A, B, or C), active power (in watts),
and age. GEE was used to adjust for the statistical depen-
dence of multiple limbs operated on for some of the pa-
tients.
The estimated effect of the risk factors is presented in
terms of the odds ratio, its confidence interval (CI), and P
value. When no cases of DVT occurred among patients
included in one of the categories of a risk factor (eg, ulcer
present compared with ulcer not present), the odds ratio
cannot be estimated, and we simply present the percentage
of cases with DVT in each category and a P value from
Fisher’s exact test for the null hypothesis that all categories
of the risk factor have the same DVT rate. The same
approach was used for the analysis of closure and closure
rates.
The logistic regression models for closure were done
with and without adjustment for the follow-up time. The
time adjustment had a minimal impact on odds ratios, CIs,
and P values, and thus only results without the time adjust-
ment are presented.
RESULTS
Endovenous laser ablation of the SSV was performed
on 210 limbs in 187 patients during a 16-month period at
a single clinic by three vascular surgeons. Concomitant
GSV reflux was present in 156 limbs (74 %), and these limbs
underwent EVLT of both the SSV and the GSV. EVLT of
the SSV alone was done in 54 limbs. Significant perforator
vein incompetence was seen in 65% of limbs.
Patient demographics and CEAP clinical classification
of limbs that underwent GSV and SSV ablation vs SSV
ablation alone are summarized in Table II. According to
the anatomic classification the SSV that we had defined, 88
(43 %) had type A anatomy, 69 (33%) had type B anatomy,
and 52 (24%) had type C anatomy. Anatomic classification
was missing for one limb.
The procedure was technically successful in 100% of
limbs. At the initial follow-up duplex scan performed 2 to 4
Table II. Demographics and CEAP classification
GSV  SSV EVLT n  156 (%)
Age (mean, range) 52 (14-89)
Gender (% female) 85
Limb (right/left) 78/78
CEAP classification
Class 2 106 (69)
Class 3 and 4 42 (27)
Class 5 and 6 8 (5)
Presence of pain (%) 97
GSV, Great saphenous vein; SSV, short saphenous vein; EVLT, endovenousdays after the procedure, 100% of SSVs were occluded. Atthe first follow-up duplex scan, 12 (5.7 %) limbs were found
to have a DVT, but no DVTs were present in any limb at
the final follow-up scan 2 to 11 months postprocedure. A
DVT was defined as thrombus extending into the popliteal
vein from the saphenopopliteal junction (Fig 2). All of the
DVTs discovered were nonocclusive and were visualized as
SSV EVLT alone n  54 (%) All limbs n  210 (%)
54 (35-85) 53 (14-89)
94 88
31/23 109/101
42 (78) 148 (70)
10 (19) 52 (25)
2 (4) 10 (5)
85 92
treatment.
Fig 2. Deep venous thrombosis is shown extending into popliteal vein
in transverse and cross-sectional views (SSV, short saphenous vein).a tail of thrombus extending beyond the saphenopopliteal
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0.3 to 4.0 cm).
The study had no protocols for treatment of the DVTs,
and clinical treatment was left to the discretion of the
surgeon who had treated the patient. Seven (58%) of the
limbs with DVT were treated in the first 6 months of the
study. The distance the clot extended into the popliteal
vein, the mode of treatment, and the duration of treatment
of all DVTs found in the study are summarized in Table III.
All patients with DVTs were treated or observed until a
duplex ultrasound scan showed the clot was completely
resolved. No clot extensions were noted during the study
period, and there were no known pulmonary emboli.
A statistical analysis was performed to ascertain factors
that would increase the risk for DVT (Table IV). No
patients with type C anatomy had a DVT. Because limbs
with this anatomic pattern had no connection between the
popliteal vein and the SSV, DVT in these limbs would be
theoretically very improbable. In the analysis, only ana-
tomic subtype was predictive of DVT. Patients with type B
anatomy had an odds ratio of 0.23 (95% CI, 0.05 to 1.10)
of DVT compared with type A anatomy (P .07), whereas
those with type C anatomy had a statistically significantly
lower risk of DVT than type A anatomy (P  .013). Odds
ratio could not be calculated for type C anatomy because
there were no DVTs in these patients.
Four patients (2%) did not return for the 6-week clini-
cal follow-up, and six patients (3%) were treated 6 weeks
from the end of the study period and therefore had not yet
had a 6-week follow-up examination. Of the patients who
had complained of pain associated with their venous insuf-
ficiency, 187 limbs were available for 6-week follow-up and
180 (96%) limbs were pain free. Of the 54 patients with
SSV incompetence alone, 46 complained of pain before the
procedure, and 45 (98%) reported resolution of pain after
Table III. Treatment of deep venous thrombosis
DVT
number Length (cm)* Treatment Duration†
1 1.0 Aspirin‡ 6 weeks
2 3.4 Lovenox/Coumadin§ 3 months
3 0.7 Lovenox 3 days
4 4.0 Lovenox/Coumadin 6 weeks
5 0.3 Observation
6 0.9 Lovenox 5 days
7 0.5 Lovenox/Coumadin 4 weeks
8 2.4 Lovenox/Coumadin 6 weeks
9 0.6 Lovenox/Coumadin 6 weeks
10 2.1 Lovenox/Coumadin 2 weeks
11 0.4 Aspirin‡ 6 weeks
12 1.7 Lovenox/Coumadin 4 weeks
DVT, Deep venous thrombosis.
*Length clot extended into saphenopopliteal junction.
†Duration of treatment until duplex ultrasound confirmed resolution of clot.
‡Aspirin dose was 325 mg, once daily.
§Lovenox, Sanofi-Aventis, Bridgewater, NJ; Coumadin, Bristol-Myers
Squibb, Princeton, NJ.the procedure.Ten limbs had ulceration, five at the medial malleolus,
four at the lateral malleolus, and one just lateral to the tibia
above the ankle in an area of trauma. All limbs showed ulcer
healing after the procedure. In the 10 limbs with ulcer,
EVLT of both the GSV and SSV was performed in eight,
and EVLT of the SSV only was performed in two. In 200
limbs (187 symptomatic, 13 nonsymptomatic) available for
6-week follow-up, no visible varicose vein branches re-
mained, as verified by before-and-after digital photographs
in 143 limbs (71%), and some remaining varicosities were
visible in 57 limbs (29%).
Patients were examined for dysesthesias and numbness
at the 2-week and 6-week follow-up. Numbness was found
at the lateral malleolus or distal posterior calf in three limbs
(1.6%). No patients complained of dysesthesias in the back
of the calf or lateral malleolus. Two of the patients with
ankle numbness had also undergone microphlebectomy of
vein branches near the lateral malleolus.
Final follow-up scans were obtained in 126 limbs
(60%). Recanalization of the SSV was seen in five limbs
Table IV. Risk factors for deep venous thrombosis
(univariate analysis)
Risk factor N DVT (%) OR (95% CI)* P*
Gender
Female 182 6.6 — .4†
Male 28 0.0 —
Leg side
Left 101 6.9 1.00
Right 109 4.6 0.64 (0.20-2.09) .5
Ulcer
No 199 6.0 — .5†
Yes 11 0.0 —
Stasis
No 148 6.8 1.00
Yes 62 3.2 0.46 (0.10-2.16) .3
Pain
No 13 0.0 — .5†
Yes 197 6.1 —
Ulcer, stasis or pain
No 11 0.0 — .5†
Yes 199 6.0 —
Anatomy type
A 88 11.4 1.00
B 69 2.9 0.23 (0.05-1.10) .07‡
C 52 0.0 — .013§
Watts
12 98 7.1 1.00
12 112 4.5 0.61 (0.19-1.98) .4
Age (per 10 years) 210 — 0.99 (0.62-1.57) .97
Watts (per 1 unit)¶ 210 — 0.81 (0.52-1.27) .4
DVT, Deep venous thrombosis; OR, odds ratio; CI, confidence interval.
*Generalized estimating equations, accounting for multiple legs for some
patients.
†Fisher’s exact test used, the P value might be slightly anticonservative.
‡Type A vs type B.
§Type A vs type C (Fisher exact test), P .5 for type B vs type C (Fisher exact
test).
Age, mean  SD: DVT, 53  12; no DVT, 53  13.
¶Watts, mean  SD: DVT, 11.3  1.4; no DVT, 11.6  1.4.(4%). Table V describes duplex ultrasound findings for each
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lized SSV segments complained of recurrent symptoms. A
logistic regression analysis of risk factors for DVT was
performed to assess risk of recanalization. The same vari-
ables as investigated for the risk of DVT were analyzed, and
no factors were found to be associated with increased risk of
recanalization.
DISCUSSION
EVLT of the GSV has been widely accepted as a treat-
ment for primary varicose veins, but is less often used in
treatment of SSV reflux. Valvular incompetence of the GSV
is the most common contributor to primary varicose veins;
however, reports of patterns of reflux show that between
13% and 20% of patients have SSV reflux as well.1,6 Fewer
reports of EVLT treatment of the SSV have been published.
Ravi et al3 reported the largest current series in 2006, which
consisted of 981 patients and included 101 SSV proce-
dures. In 2003, Proebstle et al5 reported specifically on the
treatment the SSV in 41 limbs using a 940-nm diode laser.
Reluctance of practitioners to use EVLT in the treat-
ment of SSV incompetence may be related to concerns
about the proximity of the sural nerve to the vein as well as
concerns about popliteal thrombosis. Saphenous neuralgia
is a well-known complication after GSV stripping, particu-
larly below the knee.7-9 Injury to the sural nerve,10-12 and
even to the tibial nerve,13 has been reported with SSV
stripping. Althoughmost published reports of EVLT of the
GSV note that saphenous neuralgia after treatment is either
absent2 or uncommon,14 we had noted in our own practice
that approximately 3% of patients noted numbness at the
ankle at the initial follow-up after EVLT of the GSV (per-
sonal unpublished data).
Proebstle et al5 reported paresthesias in four (11%) of
33 patients who had SSV treatment with EVLT. The
median duration of paresthesia in these patients was 6.5
weeks (range, 3 to 8 weeks).5 Only three patients (1.6%) in
our study complained of numbness at the 6-week follow-
up. In only one of these patients could EVLT alone be
implicated in causing numbness, because two of the pa-
tients also had microphlebectomy of large varicose vein
branches at the lateral malleolus. None of the patients
found the numbness to be a significant concern.
We have noted that a substantial fascial sheath almost





1 4 Small flow channel, partially compressible
2 3 Open, small, no reflux seen
3 8 Small flow channel proximally
4 3 Thick, small flow channel
5 3 Partially compressible, but no color flow seen
EVLT, endovenous laser treatment.invariably surrounds the SSV that makes creation of a largecuff of perivenous tumescence quite simple. The ease of
adequate tumescence of the SSV, which theoretically sepa-
rates the nerve from the vein, is likely why the incidence of
sural nerve injury was low in this study.
The incidence of DVT with varicose vein surgery has
not been extensively investigated, but may be as high as
5.3%, as shown in a recent study by van Rij et al.15 Risk of
DVT with EVLT of the GSV in reported series varies from
0% to 7.7%.2,3,16,17 In the first 206 GSVs treated with
EVLT in our practice (2002 to 2004), 1.9% had DVTs.18
All of the DVTs in our patients were a nonocclusive tail of
thrombus extending into the femoral vein, similar to the
appearance noted by Mozes et al.17
Differences in rates of DVTmay be related to variability
in technique, timing of follow-up ultrasound, or the defi-
nition of DVT. There are no published criteria defining
DVT after EVLT of the GSV or SSV. The criteria that we
used—any protrusion of clot into the deep vein—is admit-
tedly very conservative, and it is possible that some clot
extensions into the common femoral vein that we defined
as DVTs would not have been regarded as DVTs by other
authors. NoDVTs were observed after EVLT of the SSV by
Ravi et al,3 and a DVT was noted in one (3%) of 33 patients
by Proebstle et al.5
Our incidence of DVT after treatment of the SSV was
5.7%, higher than in the other reported series. The reason
for this difference is unclear, because patient demographics
and described techniques are similar in all three series. It is
unlikely that the difference in laser wavelength (980 nm in
our study vs 940 nm in the other studies) would explain the
higher rate of DVT in our study.
Compared with the series by Ravi et al, our patients had
earlier initial postprocedure duplex scans (day 2 to 4 com-
pared with 2 weeks). We chose to perform the first fol-
low-up duplex scan at this interval because we required all
patients to wear constant compression for 48 hours, which
made earlier scanning difficult. Some patients had their first
follow-up scan at 3 to 4 days because of an intervening
weekend. It is possible that early scanning picks up minor
DVTs that would otherwise regress. The rate of DVT in the
last 12 months of the study was 3% (5/168 limbs), imply-
ing that even though the surgeons had significant experi-
ence with EVLT of the GSV at the beginning of the study,
a learning curve still exists in the treatment of the SSV.
The influence of the anatomy of the saphenopopliteal
junction on the risk of DVT is not surprising. We and other
authors19 have noted the importance of withdrawing the
tip of the laser distal to the inferior epigastric vein when
treating the GSV. Theoretically, this preserves flow at the
saphenofemoral junction, which in turnmay prevent exten-
sion of thrombus into the femoral vein. The branching
pattern at the popliteal junction is quite variable as reported
by several anatomic duplex studies.20,21
The investigation by Delis et al,21 found that the Gia-
comini vein was present as a tributary or trunk projection in
70.4% of limbs. We found that the Giacomini vein was the
sole termination of the SSV in 24% of limbs (type C) and
was a main SSV tributary in 33% of limbs (type B). The
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DVT: 11.4% compared with 2.9% of limbs with type B
anatomy, and 0% of limbs with type C anatomy. The reason
for the increased risk in these limbs is apparent: patients
with type C anatomy have no significant risk of DVT
because of the absence of communication between the SSV
and the deep veins, and patients with type B anatomy have
the benefit of flow from the Giacomini vein into the saphe-
nopopliteal junction to maintain patency. The Giacomini
vein is analogous to the inferior epigastric vein in EVLT of
the GSV, and in patients with type B anatomy, we attempt
to position the laser fiber distal to the termination of the
Giacomini in the SSV.
These findings have relevance in counseling patients
before the procedure about their risk of DVT and also may
suggest which patients should have prophylactic anticoag-
ulation. Further study would be required to document
whether prophylactic anticoagulation prevents DVT in pa-
tients undergoing EVLT.
Although we had no set protocols for anticoagulation
or observation of patients with DVT, clot regression and
resolution was noted in all patients during the study period,
regardless of mode of treatment. Hypercoagulable state
panels were not assessed on patients with post-treatment
DVT. None of the patients with DVT had an adverse
outcome such as post-thrombotic syndrome or pulmonary
embolus. Postprocedure symptoms in the patients with
DVT were indistinguishable from those patients without
DVT, and diagnosis was made solely from routine duplex
imaging. Only one patient with a minor DVT (0.3 cm) was
observed, without treatment, so it is uncertain how these
patients would have fared without anticoagulation. The
uniformly good outcomes and lack of symptoms that these
patients have raised the question of whether these minor
clots need to be treated at all. Further study would be
required to answer this question.
The initial technical success was excellent (100%), and
patient outcomes were also quite respectable, with 96% of
patients being free from pain, and healing occurred in the
11 patients 6 weeks postprocedure. Caution must be
used, however, in the interpretation of the clinical out-
comes for relief of pain and ulcer healing. Most patients
underwent concomitant therapies, and this study does not
isolate which benefits came from the EVLT of the SSV vs
the concomitant therapies. These are very early results;
however, longer-term outcomes for SSV EVLT docu-
mented by Proebstle et al5 (39 patients, 6 months) and
Ravi3 (7 patients, 3 years) suggest that the benefit of the
procedure is durable.
Partial recanalization of the SSV was found at 3 months
in five limbs (4%) in our study. The clinical significance of
the recanalization of the SSV is uncertain, because in each
case, the SSV remained small and symptoms/varicosities
had not recurred. Although 95% of patients returned for
6-week clinical evaluations, only 60% of limbs had a final
follow-up duplex scan, limiting definitive conclusions
about mid-term recanalization of the SSV.CONCLUSION
To our knowledge, this series represents the largest
number of SSVs treated with EVLT in the literature to date.
Our data demonstrate that EVLT of the SSV is feasible and
safe, and has excellent clinical outcomes in combination
with concomitant therapies where indicated. The incidence
of nerve injury is acceptably low and not clinically signifi-
cant. The incidence of DVT was not negligible, although
no patients had an adverse outcome related to DVT or
anticoagulation. The lack of distinguishing symptoms in
patients with DVT compared with those without DVT
highlights the importance of early postprocedure duplex
ultrasound imaging to demonstrate this complication. An-
atomic factors as determined by preoperative duplex scan-
ning may be helpful in predicting which patients are at
highest risk for DVT. Further investigations may ascertain
if prophylactic anticoagulation is warranted in some pa-
tients and whether therapeutic anticoagulation for docu-
mented DVT is necessary.
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Dr Phillip Levin (Los Angeles, Calif). Dr Gibson’s elegant
and comprehensive presentation on the use of endovenous abla-
tion for short saphenous vein reflux indicates that this methodol-
ogy can be expanded to the treatment of the short saphenous vein
incompetence with very limited complications and excellent re-
sults. Furthermore, the paper provides some clarity on how the risk
of DVT after short saphenous vein surgery can be reduced. Let me
say at the outset that I have had no experience with EVLT, having
elected to use radiofrequency ablation because that modality had a
decreased incidence of perforation and allows for the continuous
feedback of treatment parameters, which indicate ongoing effec-
tiveness of ablation. Be that as it may, intermediate-term results of
both methods are similar and both are more effective than ligation
and stripping.
Dr Gibson and her colleagues’ experience of treating 210
short saphenous veins over the past 1½ years is remarkable when
compared with our experience in Los Angeles, where out of the
276 limbs that we treated with radiofrequency ablation, only 10
short saphenous veins were ablated, of which one developed a
small popliteal clot, which brings me to the first series of questions.
How many greater saphenous veins underwent EVLT during
the same study period? What were the criteria for treating short
saphenous veins, and how did you distinguish the short saphenous
vein as the main source of varicosities, skin changes, or ulcerations?
I noted that 78% of the limbs treated also had concomitant
treatment of the greater saphenous vein and 64% had adjunctive
treatment with perforator ligation. Would those two procedures
alone have relieved the patients of their varicosities?
I routinely perform the old tourniquet test during my initial
examination of patients with varicose veins to determine if the
varicosities fill with an above-knee tourniquet in place. If they do
not, then reflux is most likely proximal to the short saphenous vein,
which needs no treatment even if the ultrasound shows incompe-
tence.
Over 130 years ago, Giacomini described the vagaries of the
saphenopopliteal junction. Dr Gibson’s paper not only reaffirms
Giacomini’s findings but also gives them critical importance for
today’s vascular surgeon interested in treating the short saphenous
vein.
There is little doubt that the low incidence of DVT following
ablation of the greater saphenous vein is related to the consistency
of the anatomy at the saphenofemoral junction along with main-
taining patency of the superficial epigastric and the superficial
circumflex iliac veins during ablation. This is supported by your
previously unpublished low incidence of DVT following greaterseries. Your relatively high incidence of DVT in this series raises
concerns regarding ablation or even ligation of the short saphe-
nous vein. Would you recommend treatment of a patient with type
A anatomy, and if so, would you routinely offer prophylactic
anticoagulation?
Finally, I was intrigued by the fact that only 16% of the patients
in this series underwent microphlebectomy, because in our series,
over 90% had this adjunctive procedure in order to avoid subse-
quent surgery and treatment. I note that 29% of the patients in
your series required secondary procedures such as microphlebec-
tomy and sclerotherapy. Do the majority of varicose veins disap-
pear after ablation alone, and how do your patients accept under-
going additional therapies including surgery?
I want to congratulate the authors on an excellent and stimu-
lating paper and thank the society for the privilege of discussing it.
DrKathleen Gibson. Addressing your first question, approx-
imately 1000 great saphenous veins were treated during the same
period. In agreement with anatomic studies, roughly 20% of our
patients with venous insufficiency have small saphenous vein in-
volvement that requires treatment.
How did we determine which patients needed treatment? We
have a vascular lab associated with our practice, and our vascular
technologists are very good at vein mapping. They draw diagrams
similar to those that Dr Bergen’s group showed yesterday. We find
that there are many patients that have some “trickle reflux” or a
mild incompetence in the small saphenous vein or a branch coming
over from the great saphenous vein where the proximal small
saphenous is not incompetent. I refer to those veins as “innocent
bystander” small saphenous veins and feel they do not need treat-
ment, as often the patients have good results with only treatment of
the GSV. The patients need to have symptoms referable to the SSV
or we have to see large varicosities coming off of the SSV on duplex
evaluation. Just seeing reflux in and of itself does not mandate
treatment of the SSV.
About two thirds of our patients had microphlebectomy or
perforator ligation. Determining when and if to perform this
depends on how large the branches are coming off of the vein and
the patient’s goals. If the patient’s goals are cosmesis, I am more
likely to do more microphlebectomy or sclerotherapy. If they are
having the procedure because of pain or ulceration and do not
really have a concern whether every small blue vein in the back of
the calf is visible or not, I will do less; and I will do whatever I think
needs to be done to make them symptomatically better.
In terms of whether or not we are going to be treating type A
anatomy with prophylactic anticoagulation, I just finished this
analysis last month and my group is in discussion about whether or
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agulation. You do, however, have to weigh the fact that all patients
did pretty well even if they were treated after the DVT was
discovered rather than being treated prophylactically. We wonder
whether we would have more complications from anticoagulation
if we prophylactically treat all patients with type A anatomy. I do
use this data when I counsel patients about their risk because many
patients are concerned about deep vein blood clot and want to
know what their risk is, and I can counsel them based on their
anatomy about the likelihood that they will have a clot.
Your final question was, do the majority of the branches go
away, and if they do not, how is patient acceptance with needing
other procedures. I think that counseling them ahead of time
about what you are going to do and what they might expect is very
important. For example, the patient shown in this slide had scle-
rotherapy at the same time as her venous ablation. She had pain but
also was very concerned about the way her leg looked, and she
ended up with an excellent cosmetic result.
This patient, on the other hand, if you look closely, you can
still see some visible varicosities in the photo. On the digital
photograph after treatment she did have some visible varicosities. I
did not perform any sclerotherapy on her limb because she was an
elderly woman, was not concerned about the way the back of her
leg looked, and just wanted the edema and the pain to be better. I
think as long as you are very honest with patients up front, they do
fine with having follow-up procedures.
Dr John Bergan (LaJolla, Calif). This is an excellent paper,
and I would like to compliment Dr Gibson not only on the
presentation but also for the careful analysis, and most of all for
taking the surgery of varicose veins out of the popliteal fossa. There
is danger there. This is a technique that keeps the surgeon out of
the popliteal fossa, avoids nerve injury, and does ablate the short
saphenous vein.
Your percentage of cases was correctly correct. In 1000 vein
cases, you had about 200 small saphenous cases. So that was
proper, and I think your duplex analysis was excellent, although we
found different findings. It does not matter. You have done a
careful mapping.
The only question I have really has to do with nerve injury.
Mike Dalsing at Indiana University had a neurologist look at his
patients after saphenous surgery, and he found a rather high
incidence of nerve injury. So the question is did the surgeon
evaluate the patient after surgery or was there an objective exam-
iner, preferably a neurologist?
This is really a good study. I am pleased that you presented it,
and I hope to see it in print. Again, the program committee was
wise to pick this paper.
DrGibson. Thank you for your kind comments. In answer to
your questions, we did not have a neurologist evaluate the patient.
It was the surgeon at the 6-week visit asking the patient whether
they had any numbness or paresthesias and then performing a
“light touch” physical examination. Certainly, with any future
work it might be more relevant to have an independent examiner.
DrTimothy Liem (Portland, Ore). Kathy, I enjoyed that very
much. I think your data, regarding the variations in the anatomy of
the saphenopopliteal junction, has helped me to counsel my pa-
tients with regard to the risk for DVT when they are having small
saphenous.
Dr Lowell Kabnick has previously described a classification
system for DVTs in patients who are having saphenous ablation.
He provided some guidelines regarding how far the clot protrudes
into the lumen of either the femoral or the popliteal vein, and the
treatment recommendations varied according to that. My first
question is what do you think about a particular classification
system like that?
My second question is about hypercoagulable conditions.
Some studies indicate that in patients who present with venous
stasis ulcers, there may be a prevalence of at least 20% for factor V
Leiden. I do not know what to do with that data. I do not think
that everyone needs to be tested for thrombophilia beforehand, orafterward in patients who have DVT after having had small saphe-
nous ablation. I also wanted to comment on your reference to Dr
Proebstle’s initial article with his one DVT complication. That
patient also had a clotting disorder with a platelet count that was
markedly elevated.
Dr Gibson. Thank you. We do not use Dr Kabnick’s recom-
mendations; however, we do have our own criteria that we use for
the great saphenous vein. If the clot is protruding 0.4 mm or less,
we observe it; and if it is more, then we treat it. Typically length of
treatment is 6 weeks or less, however. Having these data now, we
may develop criteria as well that may be similar for the small
saphenous vein.
Your second question about whether or not these patients had
hypercoagulable states, we did not do routine testing on patients.
Interestingly, none of the 10 limbs with the ulcers had DVTs, but
that is an interesting thought. I have treated a number of patients
with known factor V Leiden, both with great and small saphenous
vein laser ablation, and I have treated them with Lovenox on the
day of the procedure. We have had no DVTs in any of those
patients. Whether or not they would have had it without Lovenox,
I do not know but it would be an interesting question.
Dr Elna Masuda (Honolulu, Hawaii). I really enjoyed this
wonderful paper that you presented, Kathy. I have a question
regarding where you placed the tip of the laser. We have experience
at hospital primarily with great saphenous vein ablation with laser,
angiodynamic laser, andwhat we found is there is an injury distance
from the tip of the laser that is about 1 to 2 cm beyond the tip, and
that injury zone is not really well described by the manufacturer.
Although we used to place the tip at 1 cm, because they say 1 to 2
cm, we had DVTs from that. In your series, you pointed out that
you placed the tip at 2 to 3 cm. Was that truly the site of laser
treatment? Because after tumescence you can see sometimes that
the laser tip protrudes forward, ormarches forward, and could have
injured the popliteal vein.
Dr Gibson. Good point. We always check the tip of the laser
after tumescence. We do check before and after. Also, if the patient
moves their leg at all during the procedure, it can move the laser
tip, so we always double-check it before we fire the laser. The
distance really depended on the anatomy. For type C, of course, it
does not matter; you can go all the way up into the thigh if you
want to. For type B, we tried to preserve that Giacomini however
far back it came in, and so we would go 2 to 3 cm sometimes back
from that. For type A, as the small saphenous vein curves, the laser
will not really follow that curve well, so you place the laser tip right
where it takes the curve deep to the popliteal vein, and usually, that
is 2 to 3 cm back for the saphenopopliteal junction, sometimes
even further. We had more clots early in the study, and I think that
early in the study the laser tip might have been closer to the
junction. That might be why we had more clots early than late.
Dr Rajabrata Sarkar (San Francisco, Calif). I have two tech-
nical questions. You did adjunctive phlebectomy. During any kind
of endovenous ablation, tumescence is very important to protect
the nerve. We find that tumescence distorts the varicosity, so did
you do the adjunctive procedure before you tumesced? That’s my
first question.
My second question is the laser uses hemoglobin as the
chromophore to convert to heat. Do you think if you anticoagulate
these patients, as you have discussed previously, you will have a
higher rate of recanalization or treatment failure because you will
disturb the clot that is sealing the vein? Thank you.
Dr Gibson. To answer the first question, yes, tumescence
does distort evenmore than for microphlebectomy, because I mark
all the vein branches ahead of time with the patient standing. For
sclerotherapy, tumescence makes it almost impossible. What I will
usually do if I am going to be doing sclerotherapy at the same time
is do tumescence proximally and perform laser on the very proxi-
mal part of the vein, as Dr Bergen was discussing yesterday. You do
not want a lot of foam sclerosant getting into the deep system, so
you can seal proximally with the laser, perform sclerotherapy, and
then complete the tumescence for the rest of the length of the vein.
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microphlebectomy, sometimes I will inject local anesthetic, make
small nicks in the skin over the vein, use a very tiny mosquito, and
clamp the vein so that after I complete the tumescence I already
have the vein “hooked” and can finish the microphlebectomy. I
find that actually the tumescence helps with patient comfort for the
microphlebectomy as well, and you do not need to use as much
local anesthetic in the skin.Your second question was about anticoagulation and would
we have increased rate of recanalization. I am not sure about that,
but I do not think so because when we do the laser procedure, we
have the patient in reverse Trendelenburg. We try to empty the
vein as much as possible to have the laser in contact with the vein
wall, so I think not only does the interaction with hemoglobin
cause closure of the vein but it is actually a direct endothelial injury
as well.
